SCHEMBL31227573

SCHEMBL31227573

Cc1cc(Cl)cc2ccnc(N[C@H]3CCCN(C(=O)OC(C)(C)C)C3)c12

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ANO1 Q5XXA6 2/20 0.48
▸ PIM1 P11309 4/20 0.46
▸ PIM2 Q9P1W9 4/20 0.46
▸ CNR1 P21554 1/20 0.45
▸ CNR2 P34972 1/20 0.45
▸ BTK Q06187 3/20 0.44
▸ USP30 Q70CQ3 2/20 0.44
▸ GFER P55789 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ PIK3CD O00329 1/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ PARP1 P09874 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ TRPV1 Q8NER1 1/20 0.40
▸ JAK3 P52333 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31227049 1.00 ANO1 (0.48) ANO1PIM1PIM2CNR1CNR2
SCHEMBL31227250 0.91 PIM1 (0.47) ANO1PIM1PIM2BTKUSP30
SCHEMBL31227296 0.90 PIM1 (0.46) ANO1PIM1PIM2BTKUSP30
SCHEMBL31227292 0.90 PIM1 (0.46) ANO1PIM1PIM2BTKUSP30
SCHEMBL31227221 0.89 PIM1 (0.45) ANO1PIM1PIM2BTKUSP30
SCHEMBL31227105 0.88 PIM1 (0.44) ANO1PIM1PIM2BTKUSP30
SCHEMBL31227054 0.86 PIM1 (0.49) PIM1PIM2BTKUSP30HDAC4
SCHEMBL31227548 0.86 PIM1 (0.49) PIM1PIM2BTKUSP30HDAC4
SCHEMBL31227249 0.86 PIM1 (0.49) PIM1PIM2BTKUSP30HDAC4
SCHEMBL31228023 0.86 PIM1 (0.43) ANO1PIM1PIM2CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 — — US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 ANO1 4759/4885PIM1 709/4885PIM2 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback